New hope for advanced cancer: ACR246 trial begins

NCT ID NCT06238401

First seen Nov 24, 2025 · Last updated May 14, 2026 · Updated 20 times

Summary

This early-phase study tests a new drug called ACR246 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 77 adults aged 18 to 75 will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tumor Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Cancer Hospital Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong First Medical University affiliated Cancer Hospital of Shandong

    RECRUITING

    Shandong, Jinan, 250117, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • ShangHai Chest Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200030, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • ShangHai Sixth People's Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200233, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Cancer Hospital

    RECRUITING

    Zhejiang, Hangzhou, 310022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.